NewsBenzingaRoth Capital avvia la copertura su Nautilus Biotechnology con rating Buy, annuncia un target di prezzo di 3,5 dollari Roth Capital avvia la copertura su Nautilus Biotechnology con rating Buy, annuncia un target di prezzo di 3,5 dollari Benzinga 2026.09.29 09:31 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy Rating on Sharplink With $13 Price Target Tencent's Q3 Revenue Up 8% YoY to RMB 207.3 Billion Realty Income vs. Agree Realty: Which REIT Wins on Dividends and Growth? Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage Is Wall Street Bullish or Bearish on Solventum Stock?
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage